Product Images Crenessity
View Photos of Packaging, Labels & Appearance
- Its molecular formula is C27H28ClFN2OS, and its molecular weight is 483.04 g/mol with the following structure - crenessity 01
- Figure A - crenessity 02
- Figure b - crenessity 03
- Figure c - crenessity 04
- Figure d - crenessity 05
- Figure e - crenessity 06
- Figure f - crenessity 07
- Figure g - crenessity 08
- Figure h - crenessity 09
- Figure I - crenessity 0a
- Figure J - crenessity 0b
- PRINCIPAL DISPLAY PANELNDC 70370-5025-1Crenessity(crinecerfont) capsules25 mg60 CapsulesRx only - crenessity 0c
- PRINCIPAL DISPLAY PANELNDC 70370-5050-1Crenessity(crinecerfont) capsules50 mg60 CapsulesRx only - crenessity 0d
- PRINCIPAL DISPLAY PANELNDC 70370-5100-1Crenessity(crinecerfont) capsules100 mg30 CapsulesRx only - crenessity 0e
- PRINCIPAL DISPLAY PANELNDC 70370-5250-1Crenessity(crinecerfont) oral solution50 mg/mL30 mLRx only - crenessity 0f
Product Label Images
The following 15 images provide visual information about the product associated with Crenessity NDC 70370-5250 by Neurocrine Biosciences, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Its molecular formula is C27H28ClFN2OS, and its molecular weight is 483.04 g/mol with the following structure - crenessity 01
Figure A - crenessity 02
This text seems to describe a product related to oral administration, possibly a press-in oral solution syringe bottle with an adapter. It also mentions a syringe with plunger for application.*
Figure b - crenessity 03
Figure c - crenessity 04
Figure d - crenessity 05
Figure e - crenessity 06
Figure f - crenessity 07
Figure g - crenessity 08
Figure h - crenessity 09
Figure I - crenessity 0a
Figure J - crenessity 0b
PRINCIPAL DISPLAY PANELNDC 70370-5025-1Crenessity(crinecerfont) capsules25 mg60 CapsulesRx only - crenessity 0c
This text appears to be a product description for a medication called Crenessity. Each capsule contains 25 mg of crincerfont. The recommended dosage is not available in the text. The product is child-resistant, with instructions to keep it out of reach of children. The manufacturer is identified as NEURINE®. Additional details such as prescribing information and the company's contact information are not provided in this excerpt.*
PRINCIPAL DISPLAY PANELNDC 70370-5050-1Crenessity(crinecerfont) capsules50 mg60 CapsulesRx only - crenessity 0d
PRINCIPAL DISPLAY PANELNDC 70370-5100-1Crenessity(crinecerfont) capsules100 mg30 CapsulesRx only - crenessity 0e
This text provides information about a product called "Aconly capsules" containing 100 mg of "crinecerfont" also known as Crenessity™. The package is child-resistant and has a recommended dosage to be found in the Prescribing Information. It is produced by Neurocrine Biosciences in San Diego, CA. The GTIN number is 0037037051001 with an expiration date indicated as "EXP YYYY MMM 00".*
PRINCIPAL DISPLAY PANELNDC 70370-5250-1Crenessity(crinecerfont) oral solution50 mg/mL30 mLRx only - crenessity 0f
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
